| Bioactivity | Aurora kinase inhibitor-3 is a strong and selective Aurora A kinase inhibitor with an IC50 of 42 nM, and weakly inhibits EGFR with an IC50 of >10 μM. Aurora kinase inhibitor-3 has a binding mode with the cyclopropanecarboxylic acid moiety directed towards the solvent exposed region of the ATP-binding pocket[1]. | ||||||||||||
| Name | Aurora kinase inhibitor-3 | ||||||||||||
| CAS | 879127-16-9 | ||||||||||||
| Formula | C21H18F3N5O | ||||||||||||
| Molar Mass | 413.40 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Tari LW, et al. Structural basis for the inhibition of Aurora A kinase by a novel class of high affinitydisubstituted pyrimidine inhibitors. Bioorg Med Chem Lett. 2007 Feb 1;17(3):688-91. |
Aurora kinase inhibitor-3
CAS: 879127-16-9 F: C21H18F3N5O W: 413.40
Aurora kinase inhibitor-3 is a strong and selective Aurora A kinase inhibitor with an IC50 of 42 nM, and weakly inhibits
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.